Monday 17 December, 2007

FDA warn wyeth over venlafaxine ad

The FDA today posted on its website a warning letter sent to Wyeth Pharmaceuticals Inc. over a professional journal ad for depression drug Effexor XR (venlafaxine HCl).
EFFEXOR XR is believed to work by affecting the levels of 2 naturally occurring chemicals in the brain — serotonin and norepinephrine. Because EFFEXOR XR works on these 2 chemicals, it is known as an SNRI, or serotonin-norepinephrine reuptake inhibitor.
The letter and promotional material is attached.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker